Across the whole cohort of GBM patients, the immunohistochemical expression of IGFBP6 was high (IRS ≥ 6) in 5 cases (50%) and low (IRS < 6) in the remaining 5 cases (50%). This evidence concerns the gene IGFBP6 and glioblastoma.